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Summary.-The concentration of bound sialic acid in the sera of 56 normal subjects and 65 subjects with breast cancer was measured, in order to determine (1) whether serum sialic acid concentrations are raised in breast cancer and (2) whether the concentration of sialic acid in serum reflects tumour stage. The amount of sialic acid in serum was compared to serum carcinoembryonic antigen (CEA) values.
Urinary hydroxyproline and serum alkaline phosphatase concentrations were used as indicators of bone and liver involvement. Erythrocyte sedimentation rate (ESR) was also measured.
Significantly elevated serum sialic acid concentrations were found in breast cancer, and showed correlation with tumour stage. Serum (Simmons & Rios, 1974; Simmons et al., 1971 ; Reed et al., 1974) . The changes shown to occur in the metabolism of tumour-cell sialoglvcoproteins (Warren et al., 1972) (Silver et al., 1978) and of 4 patients with metastatic breast cancer (Macbeth & Bekesi, 1962 Stage IV Group consisted of 19 patients.
The sera were stored at -22°C within 2 h of sampling, and assayed within 7 days.
Sialic acid was measured by the method of Warren (1959) after hydrolysis with 0-iN HCl at 800C for 1 h. Spectrophotometric readings were determined both at 532 nm and 549 nm to allow for correction of interfering 2-deoxyribose (Warren, 1959 When these groups were subdivided, mean sialic acid values in Stages Ilb and IIlb (24/26 patients had nodal involvement) were significantly higher than control values (P < 0.02 and P < 0-001 respectively). These results show that sialic acid level increases as lymph nodes become involved and metastatic disease develops. For the purpose of this paper, serum sialic acid levels were considered raised when the value was greater than 2 1 mm (96% of control group had serum sialic acid values <2 1 mM). When the number of patients with raised serum sialic acid concentration is examined, the relationship to tumour stage is apparent (Table III) . Serum sialic acid levels did not correlate with serum CEA levels (r= 0.15).
Serum CEA levels were considered raised at values greater than 10 ng/ml. Mean CEA levels for 20 control donors was 2-7 + 4-4 ng/ml. Inter-assay mean and s.d. for 3 pooled sera were 5-5 + 1-6 (n = 28), 20-3+2-9 (n=28) and 110+18 (n=28). Intra-assay mean and s.d. for 3 pooled sera were 0 34+0-87 (n=59), 2*0+1-54 (n=23) and 1b64+1-82 (n=24 Urinary hydroxyproline was measured in 2h urine collections (Powles et al., 1976) . Mean hydroxyproline excretion in control subjects was 29 + 8-6 mg/l (n= 25). Interassay mean and s.d. was 47 + 11 3 (n= 10) and intra-assay mean and s.d. was 44-2 + 164 (n = 9). Hydroxyproline values > 45 mg/l were considered raised.
Serum alkaline phosphatase was considered raised when > 95 i.u. in subjects over 45 years (Biochemistry ]Department, St Vincent's Hospital, unpublished results). Table III shows a comparison of the number of abnormal values in Stages I-IV of sialic acid, CEA, alkaline phosphatase, hydroxyproline and ESR. Table IV shows the relationship of these abnormal values to sites of metastases. From these and from Fig. 2 , which shows the percentage of each group with raised biochemical levels, it can be seen that the best correlation with staging is with sialic acid and CEA, followed by ESR.
DISCUSSION
We wish to analyse these results in terms of correlation with : (1) tumour stages, (2) lymph-node involvement and (3) other biochemical values (e.g. serum CEA).
Serum sialic acid levels have previously been measured in breast cancer by Macbeth & Bekesi (1962) who found no significant elevation in 36 patients with localized disease, but 4/4 patients with metastatic involvement had raised levels. Mrochek et al. (1976) studied sera of unstaged breast cancer during therapy, and noted that only 4/21 had serum sialic acid values greater than 2 x s.d. above the control mean.
We have shown that serum sialic acid concentrations were raised in breast cancer and reflected tumour stage (Fig. 1) We found no significant correlation between serum sialic acid levels and serum CEA values (P < 0 5). This would indicate that CEA and sialic acid measure different parameters, e.g. CEA is an immunological marker and sialic acid may reflect serum sialoglycoprotein derived from sources additional to tumour-cell surface.
A higher proportion of patients had raised sialic acid levels compared to raised serum CEA, in all stages of breast cancer, especially the earlier stages. Serum sialic acid was raised in 56% and serum CEA in 3300 of all breast-cancer patients. In patients with distant metastases serum sialic acid was raised in 790% compared to raised CEA in 68%, whilst 17/19 (80%) had either raised sialic acid or CEA. Coombes et al. (1977) showed that with development of metastases, the percentage of breast-cancer patients with high CEA levels ( > 20 ng/ml) was 810% and Tormey et al. (1977) reported that 76% of breast cancer patients with metastases had high (> 3 ng/ml) CEA values. These figures are similar to our series in metastatic disease (680°).
Reviewing a number of markers (Fig. 2) one can see that sialic acid seems to be the most sensitive marker of advancing disease, followed closely by CEA and ESR.
As levels of acute-phase proteins (including acid glycoprotein) rise in response to infection, inflammation, trauma and injury, care must be taken in interpreting sialic acid results. Raised serum sialic acid was also reported in tuberculosis, rheumatoid arthritis and multiple sclerosis (Macbeth & Bekesi, 1962) and raised values were found in patients with renal failure but not liver damage (Gray et al., 1976) . Whilst serum sialic acid levels are not specific for malignancy, they may be of adjunctive value in tumour-stage assessment in association with other markers.
In conclusion, serum sialic acid levels correlate with advancing stage of breast cancer, appear to be higher in patients with lymph-node metastases, and may be a more sensitive marker of advancing disease than CEA, ESR, hydroxyproline or alkaline phosphatase.
